Formulated with more than 40 percent skin care ingredients, the foundation aims to emphasize both color payoff and skin care ...

New service ensures rapid delivery of small volume clinical trial materials, solving a critical bottleneck in drug ...

The PDUFA action date for an FDA decision for linvoseltamab to treat adult patients with relapsed/refractory multiple myeloma ...

Acceptance follows resolution of third-party fill/finish manufacturing issues FDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc.

Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...

Regeneron, which is seeking FDA approval of linvoseltamab for adults with relapsed/refractory multiple myeloma that has progressed after at least three prior therapies, said the agency set a new ...

Regeneron (REGN) announced that the U.S. Food and Drug Administration has accepted for review the resubmission of the Biologics License ...

Download and save the PDF to your computer Open the downloaded PDF in Acrobat Reader 10 or later The t2200 form must be completed by employers in order for their employees to deduct employment ...

Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report fourth-quarter and full-year 2024 results on Feb. 4, 2025. The Zacks Consensus Estimate for fourth-quarter revenues is pegged ...

Pune, Jan. 29, 2025 (GLOBE NEWSWIRE) -- Fill-Finish Manufacturing Market Size & Growth Analysis: According to SNS Insider, the global Fill-Finish Manufacturing Market size was valued at USD 15.4 ...